Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib.
Allison Ackerman
No relevant relationships to disclose
David F. McDermott
Consultant or Advisory Role - Bristol-Myers Squibb; Prometheus; Roche/Genentech
Donald P. Lawrence
No relevant relationships to disclose
Anasuya Gunturi
No relevant relationships to disclose
Keith T. Flaherty
Consultant or Advisory Role - Roche/Genentech
Anita Giobbie-Hurder
No relevant relationships to disclose
F. Stephen Hodi
Consultant or Advisory Role - Bristol-Myers Squibb (U); Roche/Genentech (U)
Research Funding - Bristol-Myers Squibb; Roche/Genentech
Nageatte Ibrahim
No relevant relationships to disclose
Michael B. Atkins
Consultant or Advisory Role - Bristol-Myers Squibb; Prometheus; Roche/Genentech
Daniel C. Cho
No relevant relationships to disclose
Ryan J. Sullivan
No relevant relationships to disclose